

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 209/88, 491/052, A61K 31/40 // (C07D 491/052, 311:00, 209:00)		A1	(11) International Publication Number: WO 98/04527 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/12782			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, I.U, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 July 1997 (22.07.97)			
(30) Priority Data: 08/687,849 26 July 1996 (26.07.96) US			
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).			
(72) Inventors: KREFT, Anthony, Frank, III; 43 Barley Court, Langhorne, PA 19047 (US). CAUFIELD, Craig, Eugene; 28 Cranbury Road, Princeton Junction, NJ 08550 (US). FAILLI, Amedeo, Arturo; 14 Landing Lane, Princeton Junction, NJ 08550 (US). CAGGIANO, Thomas, Joseph; 350 Stockham Avenue, Morrisville, PA 19067 (US). GREENFIELD, Alexander, Aleksey; 122 Harris Road, Princeton Junction, NJ 08550 (US). KUBRAK, Dennis, Michael; 3231 Gaul Street, Philadelphia, PA 19134 (US).		Published <i>With international search report.</i>	
(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.			

(54) Title: PYRANOINDOLE AND CARBAZOLE INHIBITORS OF COX-2

(57) Abstract

This invention provides compounds of formula (I) wherein R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aralkoxy, trifluoroalkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido; R₅ is hydrogen, alkyl, alkenyl, alkoxyalkyl or alkylcycloalkyl; R₆ is hydrogen, alkyl or alkenyl; X is oxygen or carbon; A is oxygen or NZ; Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in the treatment of arthritic disorders, colorectal cancer, and Alzheimer's disease.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

PYRANOINDOLE AND CARBAZOLE INHIBITORS OF COX-2**5 FIELD OF THE INVENTION**

This invention is in the fields of antiinflammatory and anticancer pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis and for treating 10 colorectal cancer.

BACKGROUND OF THE INVENTION

Prostaglandins have been shown to be involved in the pathophysiology of 15 several chronic human diseases. They are involved as mediators of pain, edema and vascular permeability in arthritic diseases such as rheumatoid arthritis and osteoarthritis (Lewis and Kreft, *Immunopharmacol. Immunotoxicol.* 17, 607-663 (1995)). In addition, prostaglandins have been postulated to be involved in the pathophysiology of 20 colorectal cancer (Marcus, *New Eng. J. Med.* , 333, 656-657 (1995)). Thus an agent that inhibits prostaglandin synthesis may be useful in treating these disorders.

The biosynthesis of prostaglandins was previously thought to be due to the action of a single cyclooxygenase enzyme on arachidonic acid to afford prostaglandin H₂ (Vane et al., *Postgrad. Med. J.* , 66 (Suppl 4), S2-S17 (1990), Lewis and Kreft, *Immunopharmacol. Immunotoxicol.* 17, 607-663 (1995)). This intermediate is 25 subsequently transformed into the various members of the prostaglandin family by more distal enzymes. The clinical utility of cyclooxygenase inhibitors (often called NSAIDs: nonsteroidal antiinflammatory drugs) is well established in arthritic disorders (Brooks et al, *New Eng. J. Med.* , 324, 1716-1725 (1991)); however, these compounds have serious G.I. side effects due to the importance of prostaglandins in the 30 maintenance of gastrointestinal functioning and renal blood flow (Dajani et. al., *J Physiol Pharmacol.*, 46, 3-16 (1995); Somasundaram et al, *Scand. J. Gastroenterol.*, 30, 289-299 (1995)). Under the old paradigm of a single cyclooxygenase enzyme it appeared that the selective inhibition of prostaglandin synthesis in inflamed tissue 35 versus inhibition of prostaglandin synthesis in G.I tissue was unlikely unless tissue specificity could be achieved.

Recently the discovery that there are two distinct cyclooxygenase enzymes has given rise to a new paradigm which may lead to compounds that have a separation of inhibition of prostaglandin synthesis in inflamed tissue from inhibition of prostaglandin synthesis in G.I tissue (Hayllar, *Lancet*, 346, 521-522 (1995), Lewis and Kreft,

- 2 -

Immunopharmacol. Immunotoxicol. **17**, 607-663 (1995)). In the new paradigm the constitutive cyclooxygenase enzyme responsible for prostaglandin synthesis in G.I tissue is termed COX-1 and the inducible cyclooxygenase enzyme responsible for prostaglandin synthesis in inflamed tissue is termed COX-2. Several groups have

5 reported that NSAIDS vary in their ability to inhibit COX-1 and COX-2 so that selective inhibition may be possible (O'Neill et al, *Molec. Pharmacol.* , **45**, 245-254 (1994); Laneuville et al., *J. Pharmacol. Exp. Ther.* , **271**, 927-934 (1994); Mitchell et al, *Proc Natl. Acad. Sci. USA* , **90**, 11693-11697 (1993)). It is hoped that a selective COX-2 inhibitor would not only have clinical efficacy in inflammatory diseases but also would

10 lack G.I toxicity. There is evidence from animal models to support this hypothesis (Chan et. al., *J. Pharmacol Exp.Ther.* **274**, 1531-1537 (1995); Masferrer et. al., *Proc. Natl. Acad. Sci. USA* , **91**, 3228-3232 (1994); Seibert et al . *Proc. Natl. Acad. Sci. USA* , **91**, 12013-12017 (1994)). Moreover, this may be the mechanism behind the improved G.I. safety of the NSAID etodolac which has a tenfold selectivity for

15 inhibition of COX-2 (Glaser et. al., *Eur. J. Pharmacol.* **281**,107-111 (1995)). Thus novel COX-2 inhibitors appear as attractive targets for antiarthritic therapy with potential to reduce G.I side effects. In addition, the COX-2 enzyme has been shown to be upregulated in colorectal cancer and a selective COX-2 inhibitor may also be of use in this disease (Sano et. al., *Cancer Res.* , **55**, 3785-3789 (1995)). In addition,

20 indomethacin, a relatively non-selective inhibitor of COX-2 with adverse G.I. side effects, has been shown to be useful in the treatment of Alzheimer's disease (Rogers et. al., *Neurology*, **43**, 1609-1611 (1993)) which suggests that a COX-2 selective inhibitor would be not only useful for the treatment of Alzheimer's disease but also a safer therapy with fewer G.I. side effects.


25 Humber et al have described the 10 step synthesis of the 4-oxo analog of the 1,3,4,9-tetrahydropyrano[3,4-b]indole, etodolac (*J.Med. Chem.* **31**, 1712-1719 (1988); U.S. Pat. No. 4,686,213). The 4-oxo metabolite was active in blocking prostaglandin synthesis and had oral in vivo antiinflammatory activity. In this invention we not only describe new analogs of this compound beyond the limited scope of U.S.

30 Patent 4,686,213 but also detail an improved 4 step synthesis for preparing this metabolite as well as previously unknown 4-imino analogs and their activity against the COX-2 enzyme.

- 3 -

DESCRIPTION OF THE INVENTION

In accordance with this invention, there are provided COX-2 inhibitors which are useful as antiarthritic, anticancer and antiAlzheimers agents of formula I:



5

wherein

10 R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkylmido of 2-6 carbon atoms, or alkylsulfonamido of 1-6 carbon atoms;

15 R₅ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

20 R₆ is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

25 X is oxygen or carbon;

25 A is oxygen or NZ;

25 Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

25 or a pharmaceutically acceptable salt thereof.

30 This invention provides both the R and S stereoisomers of the C-1 alkanoic acid, as well as to mixtures of the R and S stereoisomers. Throughout this application, the name of the product of this invention, where the absolute configuration of the C-1 alkanoic acid is not indicated, is intended to embrace both R and S enantiomers as well as mixtures of the two. The terms alkyl, alkenyl, and alkynyl include both straight

- 4 -

chain as well as branched moieties. The term halo includes fluorine, chlorine, bromine, and iodine.

It is preferred that the aryl moiety is a phenyl group which may be optionally 5 mono-, di-, or tri-substituted with a substituent or substituents such as alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halogen, nitro, carboalkoxy of 2-7 carbon atoms, -CF₃, -OCF₃, -OCH₂CF₃, amino, dialkylamino of 1-6 carbons per alkyl group, alkoxyalkyl of 2-12 carbon atoms, alkylthio of 1-6 carbon atoms, SO₃H, PO₃H, and CO₂H.


10 Preferred compounds of this invention include those in which R₆ is hydrogen; those in which R₆ is hydrogen and R₅ is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms; those in which R₆ is hydrogen, R₅ is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon 15 atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms, and A is oxygen; and those in which R₆ is hydrogen, R₅ is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms, X is CH₂ or oxygen and A is NZ where Z is OH or NHSO₂alkyl in which each alkyl moiety has 1-6 carbon atoms.

20 The pharmaceutically acceptable salts include those derived from organic and inorganic acids such as, but not limited to: acetic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, toluenesulfonic and similarly known acceptable acids. 25 Carboxylate salts, preferably alkali metal salts, for example, sodium or lithium, may also be prepared as salts of carboxylic acids where R₆ is hydrogen.

30 The compounds having the formula I as illustrated above where A, R₁, R₂, R₃, R₄, R₅, R₆ and X are as defined above and their pharmaceutically acceptable salts may be prepared by a process which comprises:

- 5 -

(a) oxidation of a compound having the formula II



5 where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and X are as defined above or a salt thereof so as to prepare a compound having the formula I as illustrated above in which A is oxygen and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and X are as defined above or a salt thereof; or

10 (b) reaction of a compound having the formula I where A is oxygen and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and X are as defined above or a salt thereof with a compound having the formula H_2NZ where Z is as defined above to prepare a compound having formula I as illustrated above where A is NZ and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and X are as defined above or a salt thereof; or

15 (c) hydrolysis of a compound having formula I as illustrated above where A, R_1 , R_2 , R_3 , R_4 , R_5 , and X are as defined above and R_6 is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms so as to form a compound having formula I as illustrated above where A, R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and X are as defined above and R_6 is hydrogen or a salt thereof.

20 In addition a compound of the invention may be converted into a salt thereof (or such a salt may be converted into a compound of the invention). Such a conversion may be carried out by addition of an acid or a base as appropriate.


25 The 4-oxo-1,2,3,4-tetrahydro-4H-carbazole-1-alkanoic acids of this invention can be conveniently prepared by oxidation of the corresponding carbazole (prepared via Fischer indolization of the appropriate cyclohexanone with the appropriately substituted phenylhydrazine) with either 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or 2,2,6,6-tetramethyl-piperidine-1-oxonium tetrafluoroborate (TEMPO BF_4); the related

30 4-imino compounds can be preferably prepared by reaction of the 4-oxo esters with appropriately substituted amines followed by hydrolysis of the ester moiety (Scheme

- 6 -

1). The starting materials or intermediates are available commercially or can be prepared by standard literature procedures.

Scheme 1




5

4-oxo 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-alkanoic acids can be prepared by oxidation of the corresponding 1,3,4,9-tetrahydropyrano[3,4-b]indole (prepared, in turn, via cyclization of the appropriately substituted tryptophol with an alkoxy enol ether) with either 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or 2,2,6,6-tetramethyl-piperidine-1-oxonium tetrafluoroborate (TEMPO BF4); the related 4-imino analogs can be preferably prepared by reaction of the 4-oxo esters with various substituted amines followed by hydrolysis of the ester moiety (Scheme 2).


- 7 -

Scheme 2



In addition, other functionalized analogs may be prepared by displacement of a bromo substituent such as shown in Scheme 3 (R₁=Br).

Scheme 3



The compounds of this invention inhibit the COX-2 enzyme which is believed to be responsible for the production of high levels of prostaglandins in inflammation and colorectal cancer (Tables 1-3). It has been shown that selective inhibition of the COX-2 enzyme relative to COX-1 inhibition leads to an antiinflammatory effect without G.I. toxicity (Chan et. al., *J. Pharmacol Exp. Ther.* **274**, 1531-1537 (1995); Masferrer et. al., *Proc. Natl. Acad. Sci. USA*, **91**, 3228-3232 (1994); Seibert et al., *Proc. Natl. Acad. Sci. USA*, **91**, 12013-12017 (1994)). Therefore, the compounds of this invention are useful for the treatment of inflammatory diseases such as rheumatoid arthritis. In addition, compounds that selectively inhibit the COX-2 enzyme are expected to have a greater margin of safety.

The compounds of this invention were evaluated for inhibition of COX-2 and COX-1 as follows: human COX-1 and COX-2 cDNAs were cloned from human monocytes, untreated and LPS treated, respectively, by RT-PCR using oligonucleotide primers based on published rhCOX-1 and rhCOX-2 sequences (Jones et al, *J. Biol. Chem.*, **268**, 9049 (1993)). The cDNAs were then transfected into either Sf9 or CHO cells and subsequently converted into a microsomal preparation as described by Glaser et al (*Eur. J. Pharmacol.* **281**, 107-111 (1995)). The microsomal human recombinant enzymes were diluted with buffer (100 mM Tris, pH 7.8 at 37°C) containing 0.5 mM phenol (964 μl total volume). The enzyme preparations were preincubated with vehicle (DMSO) or compounds in DMSO (1% DMSO in final assay) for 30 min at 37°C. Excess hematin was added 1 min prior to initiation of reaction (1.25 μM final hematin)


- 9 -

with 30 μ M arachidonic acid (sodium salt). Final assay volume was 1.0 ml (100 mM Tris (pH7.8), 0.5 mM phenol, 1.25 μ M hematin and 30 μ M arachidonic acid at 37°C).

The reaction was incubated for 35 s (maximum level of PGH₂ accumulation as determined from time course studies), and terminated by addition of 50-60 μ l of SnCl₂ (1 mg/ml) in 0.1 N HCl. PGH₂ is quantitatively converted to PGF_{2a} by this reaction (50% efficiency of total conversion). The pH of each tube is adjusted to pH 3.0-3.5 with 1N NaOH and extracted twice with 1.5 ml of ethyl acetate (75-90% efficiency per extraction). Combined ethyl acetate layers were dried under N₂ (g) and redissolved in EIA buffer (2.0 ml), and PGF_{2a} was quantified by EIA.

The results of the standard pharmacological test procedure described in the preceding paragraphs were as follows:

Table 1 Inhibition of rhCOX-1 and COX-2 by 4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indoles




20	<u>Exam</u>	<u>R1</u>	<u>R3</u>	<u>R4</u>	<u>R5</u>	<u>% Inhib of rhCOX-2 (IC₅₀)</u>	<u>% Inhibition of rhCOX-1</u>
	1	H	H	H	Et	(2.1 μ M)	42% at 90 μ M
	2	H	H	H	nPr	(3.2 μ M)	44% at 90 μ M
	3	H	H	H	CH ₂ OCH ₃	8% at 3 μ M	
	4	H	H	Et	Et	(1.9 μ M)	(>270 μ M)
25	5	Cl	H	H	Et	(1.2 μ M)	
	6	Br	H	H	Et	(1.1 μ M)	
	7	CN	H	H	Et	7% at 1 μ M	
	8	H	F	allyl	Et	(0.37 μ M)	78% at 3 μ M

R₂=H for all compounds in Table 1

- 10 -

Table 2 Inhibition of rhCOX-1 and COX-2 by 4-oxo-1,2,3,4-tetrahydro-4H-carbazoles

5




	<u>Exam</u>	<u>R1</u>	<u>R3</u>	<u>R4</u>	<u>R5</u>	<u>% Inhib of rhCOX-2 (IC50)</u>	<u>% Inhibn of rhCOX-1</u>
10	9	H	H	H	Et	26% at 3 μ M	
	10	H	H	Et	Et	(2.0 μ M)	26% at 90 μ M
	11	H	H	iPr	Et	40% at 3 μ M	85% at 90 μ M
	12	Cl	H	H	Et	12% at 1 μ M	5% at 30 μ M
	13	F	H	F	Et	25% at 1 μ M	
15	14	H	F	F	Et	(0.7 μ M)	50% at 23 μ M
	15	F	H	F	allyl	30% at 1 μ M	
	16	F	H	F	nPr	29% at 1 μ M	
	17	F	F	H	nPr	13% at 1 μ M	

R2=H for all compounds in Table 2

- 11 -

Table 3 Inhibition of rhCOX-1 and COX-2 by 4-imino-1,2,3,4-tetrahydro-4H-carbazoles and 1,3,4,9-tetrahydropyrano[3,4-b]indoles



5

<u>Exam</u>	<u>R1</u>	<u>R3</u>	<u>R4</u>	<u>R5</u>	<u>X</u>	<u>Z</u>	<u>Inhib rhCOX-2</u>	<u>% Inhib rhCOX-1</u>
18	H	H	Et	Et	O	OH	50% at 3.3 μ M	96% at 90 μ M
19	H	H	Et	Et	O	NSO2CH3	50% at 3.3 μ M*	96% at 90 μ M *
20	H	H	Et	Et	CH2	OH	18% at 1 μ M	

10 R2=H for all compounds in Table 3

* Sodium salt

Based on the results shown in the tables above, the compounds of this invention demonstrated high inhibition of the human COX-2 isozyme and are therefore 15 useful for the treatment of inflammation and inflammation-associated disorders, as an anticancer agent, and other disease states where a role for the COX-2 enzyme in producing high levels of prostaglandins has been proposed. In particular, the compounds of this invention are useful in treating arthritic disorders, such as rheumatoid arthritis; Alzheimers disease; and colorectal cancer.

20

Certain of the examples in the claims of the invention also demonstrated high selectivity for inhibition of the human COX-2 isozyme and would be expected to have a greater margin of G.I. safety, thereby facilitating patient compliance.

25

The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a

- 12 -

finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets, preferably, contain up to 99% of the active ingredient. Suitable 5 solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

10 Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, 15 buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and 20 polyhydric alcohols e.g. glycols) and their derivatives and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

25 Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

30 Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or 35 tablet itself, or it can be the appropriate number of any such compositions in package form.


- 13 -

The amount of therapeutically active compound that is administered and the dosage regimen for treating a specific arthritic disorder or colorectal cancer with the compound and/or compositions of this invention depends on a variety of factors, including the weight, age, sex, medical condition of the subject, the severity of the disease, the route and frequency of administration, and the specific compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredient in the range of 0.1 to 2000 mg, preferably in the range of 0.5 to 500 mg and most preferably between 1 and 100 mg. Projected daily dosages of active compound are 0.01 to 100 mg/kg body weight. The daily dose of can be administered in one to four doses per day.

The following examples illustrate the preparation of representative compounds of this invention.

15

Example 1



20

(1-Ethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid.

To a stirred solution at room temperature under nitrogen of 1-ethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid methyl ester (Demerson et al *J.Med. Chem.* **18**, 189-191 (1975), 0.271 g, 1 mmol) in 20 ml of dichloromethane-methanol mixture (9:1) was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.5 g, 2.2 mmol). After 30 min of stirring when TLC showed ~90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml) and sodium sulfite (10 ml of a 10% solution). The resulting mixture was stirred for ~10 min (until substantial discoloration occurred) and diluted with 1 N NaOH solution (20 ml). Extraction with ethyl acetate (50 ml x 3) followed by evaporation of the solvent gave a light brown powder. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.2 g (70 %) of the methyl ester which gave after hydrolysis (48 h, MeOH/2.5 N NaOH), 0.181 g (95 %) of the desired product as a solid, m.p. 235-238°C.

- 14 -

Analysis for: C₁₅H₁₅NO₄


Calculated: C, 65.93; H, 5.53; N, 5.13.

Found: C, 64.81; H, 5.66 ; N, 4.85.

5 ¹H NMR (400 MHz, DMSO): δ 12.24 (s, 1 H), 12.04 (s, 1 H), 7.2 - 8.1 (m, 4 H),
IR (KBr, cm⁻¹): 3420, 2960, 1720, 1620, 1470.
MS [(-)FAB m/z]: (M-H)⁻ 272.

10

Example 2



(1-Propyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid.

15 The title compound was prepared from 1-propyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid methyl ester (Demerson et al *J.Med. Chem.* **18**, 189-191 (1975), 0.286 g, 1 mmol) using the method of Example 1. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.226 g (75 %) of the methyl ester which gave after hydrolysis (48 h, MeOH- 2.5 N NaOH) 0.205 g (95 %)
20 of the desired product as a solid, m.p. 206-208°C.

Analysis for: C₁₆H₁₇NO₄

Calculated: C, 66.89; H, 5.96; N, 4.87.

Found: C, 66.74; H, 5.95; N, 4.73.


25 ¹H NMR (400 MHz, DMSO): δ 12.22 (s, 1 H), 12.02 (s, 1 H), 7.1-8.0 (m, 4 H),
4.2 - 4.4 (dd, 2 H), 2.8 - 3.1 (dd, 2 H), 1.9 - 2.2 (m, 2 H), 1.1 - 1.4 (m, 2 H), 0.85 (t, 3 H).

IR (KBr, cm⁻¹): 3400, 2950, 1710, 1620, 1460.

MS [(-)FAB m/z]: (M-H)⁻ 287.

- 15 -

Example 3



5 (1-Methoxymethyl)-4-oxo-1,3,4,9-tetrahydro-pyran[3,4-b]indol-1-yl)-acetic acid

A. (1-Methoxymethyl)-1,3,4,9-tetrahydro-pyran[3,4-b]indol-1-yl)-acetic acid.

To a stirred solution of tryptophol (0.8 g, 5 mmol) and methyl 3,4-dimethoxy-10 2-butenoate (0.96 g, 6 mmol) in dichloromethane (15 ml, under inert atmosphere) in a 50 ml flask equipped with a magnetic stirrer at room temperature under nitrogen was added dropwise boron trifluoride etherate (0.15 ml, 1.22 mmol). After completion of the reaction (~2 h, monitoring by TLC), the mixture was diluted with 50 ml of dichloromethane and quenched with 50 ml of pH 7 buffer. The layers were separated 15 and the aqueous layer was washed with dichloromethane. The combined organic fractions were washed with brine and dried over sodium sulfate. Purification by flash chromatography (hexane:EtOAc= 3:1) afforded 1.15 g (80%) of colorless crystals that were subjected to hydrolysis in 40 mL of 3:1 mixture MeOH: 1 N NaOH. After the reaction was complete (24 h., monitored by TLC), methanol was removed *in vacuo*, 20 the mixture was diluted with water (30 mL), and the neutral components were extracted with ethyl acetate (25 mL x 2). The water layer was acidified with 1 N HCl and the product extracted with ethyl acetate (50 mL x 3). The crude material obtained after evaporation of the solvent was redissolved in dichloromethane and precipitated with hexane. Final filtration afforded, after drying, 1.04 g (95%) of the desired product as a 25 solid, m.p. 135-140°C.

Analysis for: C₁₅H₁₇NO₄

Calculated: C, 65.45; H, 6.18; N, 5.09.

Found: C, 64.84; H, 6.25; N, 4.97.

¹H NMR (400 MHz, DMSO): δ 11.97 (s, 1 H, broad), 10.62 (s, 1 H), 6.9-7.2 (m, 30 4 H), 3.98 (m, 2 H), 3.6 - 3.8 (dd, 2 H), 3.3 (s, 3 H), 2.8 (dd, 2 H)

IR (KBr, cm⁻¹): 3320, 2900, 1700, 1450.

MS (EI m/z): [M⁺] 275, 244, 230.


- 16 -

B. (1-Methoxymethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid.

To a stirred solution at room temperature under nitrogen of (1-methoxymethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid methyl ester (0.29 g, 1 mmol) in 5 ml of benzene and 5 ml of pH 4 buffer was added dropwise over 1.5 h a solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (1.135 g, 5 mmol) in benzene (30 ml). After 8 h of stirring when the TLC showed ~90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml), and sodium sulfite (10 ml of a 10% solution). The resulting mixture was stirred for ~10 min (until substantial discoloration occurred), and diluted with 1 N NaOH solution (20 ml). Extraction with ethyl acetate (50 ml x 3), followed by evaporation of the solvent gave a light brown powder. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.195 g (65 %) of methyl ester which gave after hydrolysis (24 h, MeOH- 1 N NaOH), 0.170 g (90%) of the title compound as a solid, m.p. 135-140°C.

15 Analysis for: C₁₅H₁₅NO₅
Calculated: C, 63.36; H, 5.65; N, 4.62.
Found: C, 61.60; H, 5.16; N, 4.70.
16 ¹H NMR (400 MHz, DMSO): δ 12.0 (s, 1 H), 7.18-7.9 (m, 4 H), 4.0-4.4 (dd, 2 H), 3.7 - 3.9 (dd, 2 H), 3.26 (s, 3 H), 2.8-3.2 (dd, 2 H)
17 IR (KBr, cm⁻¹): 3360, 2900, 1720, 1640, 1460.
18 MS (EI): 289, 244.

Example 4



25

1.8-Diethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid

A. 1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid methyl ester
30 1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]-1-indole acetic acid (5.0g, 17.4 mmol) (Demerson et al *J. Med. Chem.* **19**, 391-395 (1976)) was dissolved in MeOH

- 17 -

and H₂SO₄ (2.12 g, 21.6 mmol) was added dropwise. After overnight stirring, the mixture was concentrated, and the precipitate filtered, washed with water, and dried in vacuo to yield the title compound as a solid, 4.68 g, m.p. 130-132°C.

5 B. 1,8-Diethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid methyl ester.

The ester produced in step A (0.5g, 1.66mmol) was dissolved in 5 ml of a 90% THF/water solution, and to this was added 2,3-dichloro-5,6-dicyano-1,4-benzo-quinone (0.75 g, 3.3 mmol., previously dissolved in 5 ml THF). This mixture was 10 stirred overnight. The solvent was evaporated and 50 ml of ethyl acetate was added. The organic phase was extracted sequentially with 2.5N NaOH, distilled water and brine. The organic layer was separated, dried (MgSO₄) and evaporated to produce 0.56 g of crude oil. The oil was flash chromatographed using CH₂Cl₂-EtOAc 98-2 as eluant to yield 0.15 g of the desired product as a solid, m.p. 187-189°C.

15 Analysis for: C₁₈ H₂₁ N O₄

Calculated: C, 68.55; H, 6.71; N 4.44.

Found: C, 68.54; H, 6.55; N, 4.44.

C. 1,8-Diethyl-4-oxo-1,3,4,9-tetrahydro-pyrano-[3,4-b]indole-1-acetic acid

20 A solution of the product produced in step B (1.25g, 3.9mmol), K₂CO₃ (3.5g, 25.3mmol) and 60 ml MeOH/H₂O 1:1 was refluxed for 3 h. The methanol was evaporated, and the aqueous residue acidified to pH 1 using 6N HCl. The aqueous phase was extracted with EtOAc. The organic phase was washed with water, dried (MgSO₄), and evaporated to produce a crude glass which was recrystallized from 25 EtOAc-hexane to afford 1.1 g of the title compound as a solid, m. p. 198-201°C.


Analysis for: C₁₇ H₁₉ N O₄

Calculated: C, 67.76; H, 6.36; N 4.65.

Found: C, 67.38; H, 6.33; N, 4.51.

- 18 -


Example 5



5 (5-Chloro-1-ethyl-4-oxo-1,3,4,9-tetrahydro-pyranolo[3,4-b]indol-1-yl)-acetic acid

To a solution of 5-chloro-1-ethyl-1,3,4,9-tetrahydropyranolo[3,4-b]indole-1-acetic acid (Demerson et al *J.Med. Chem.* 19, 391-395 (1976), 0.990g, 3.37 mmole) in methanol (30 ml) was added concentrated HCl (0.325 g), and the mixture was stirred at room temperature overnight. The methanol was removed and water added to the residue. 1N NaOH was added and the mixture extracted with ethyl acetate. The combined extracts were dried (MgSO_4), and concentrated to a gummy solid which was triturated (ethyl acetate-hexane) to afford 0.425 g solid. The solid was dissolved in 9:1 tetrahydrofuran-water (5 ml) and treated with a solution of TEMPO⁺ BF_4^- (0.663 g, 2.72 mmole) in 9:1 tetrahydrofuran-water (5ml). After stirring for one hour, the mixture was concentrated, and water added to the residue. The mixture was extracted with ether, dried (MgSO_4) and concentrated to an oil. Flash chromatography (eluting with 95:5 methylene chloride-ethyl acetate) afforded 0.240 g of product which was hydrolyzed by treating with 1N LiOH (3 ml) and THF (6 ml) overnight. After the solvent was removed, water was added to the residue and this extracted with methylene chloride. The aqueous layer was acidified (pH 2) and the resulting solid removed, extracted into ethyl acetate, dried (MgSO_4), and concentrated. The solid was recrystallized (ethyl acetate-hexane) affording a pink powder (0.096 g), m.p. 240-243°C.

Analysis for: C₁₅H₁₄ClN₁O₄
 25 Calculated: C, 58.55; H, 4.59; N, 4.55.
Found: C, 58.21; H, 4.44; N, 4.41.

Example 6

5

(5-Bromo-1-ethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acidA. 4-(3-Bromophenylhydrazone)-1-butanol

Under anhydrous conditions a solution of 3-bromophenylhydrazine hydrochloride (22.5 g, 100 mmol) and 2,3-dihydrofuran (7.55 ml, 100 mmol) in 200 ml of dry THF was stirred at ambient temperature for 3 h. The reaction mixture was partitioned between EtOAc and H₂O. The organic phase was washed with H₂O and brine. After drying (Na₂SO₄), the solvent was evaporated to give 25.6 g of the product as a brown oil. The product was of suitable purity for use in the next step.

15 ¹H_NMR (DMSO-d₆, 300 MHz): δ 1.6 (m, 2H, CH₂CH₂CH₂), 2.2 (m, 2H, CHCH₂), 3.15 (m, 2H, CH₂OH), 6.45+6.8 (m, 2H, vinyl H+ ArH), 7.05 (m, 2H, ArH), 7.2 (m, 1H, ArH), 9.25+9.85 (s, 1H, NH).

B. 1:1 Mixture of 4-bromotryptophol and 5-bromotryptophol

20 Under an atmosphere of nitrogen, a mixture of the crude hydrazone (25.4g, 98.8 mmol, prepared as described in Step A) and zinc chloride (27.2g, 200 mmol) in 200 ml of ethylene glycol was heated at 160 °C for 3 h. Upon cooling the reaction mixture was partitioned between Et₂O and dilute HCl. The organic phase was washed with H₂O and brine. After drying (Na₂SO₄), the solvent was evaporated to afford 22.7 g of a 1:1 mixture of 4 and 5 bromo compounds as a brown oil.

25 ¹H_NMR (DMSO-d₆, 300 MHz): δ 2.8 (t, 1H, ArCH₂C), 3.05 (t, 1H, ArCH₂C), 3.65 (m, 2H, OCH₂C), 6.9-7.5 (m, 4H, ArH), 10.9 (s, 0.5H, NH), 11.15 (s, 0.5H, NH).

- 20 -

C. 5-Bromo-1-ethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid methyl ester

Under anhydrous conditions, a solution of the mixture of tryptophols (22.6g, 94.1mmol, prepared as described in Step B), and methyl 3 methoxy- 2 pentenoate (13.5, 94.1 mmol) in 200 ml of dry CH_2Cl_2 was treated dropwise with boron trifluoride etherate (13.35g, 94.1 mmol) via syringe. The solution was stirred at ambient temperature for 2 h, and then washed with saturated NaHCO_3 and brine. Upon drying (Na_2SO_4), the organic phase was passed through a pad of silica gel. The filter cake was washed with additional CH_2Cl_2 and the combined organic layer was evaporated to provide 23 g of product as a mixture of regioisomers. The title compound was isolated via flash chromatography (silica gel, toluene-EtOAc, 9:1) to provide 1.4 g of the title compound, m.p 118-119°C. An additional 3.6 g of product was obtained by recrystallizing the recovered mixed products from Et_2O and petroleum ether and seeding with pure product.

15 Analysis for: $\text{C}_{16}\text{H}_{18}\text{BrNO}_3$

Calculated: C, 54.56; H, 5.15; N, 3.98.

Found: C, 54.34; H, 5.07; N, 3.98.

16 $^1\text{H NMR}$ (DMSO- d_6 , 400 MHz): δ 0.615 (t, 3H, CCH_3), 1.95 (q, 2H, CCH_2CH_3), 2.76 (d, 1H, CCH_2CO), 2.96 (m, 3H, CCH_2), 3.32 (s, 3H, OCH_3), 3.9 (m, 2H, CCH_2O), 6.93 (t, 1H, ArH), 7.11 (d, 1H, ArH), 7.32 (d, 1H, ArH), 11.148 (s, 1H, NH).17

MS (m/z, EI): 351/353 (M)⁺, 322/324 (M- C_2H_5)⁺, 278/280 (b.p., M- CH_2COOH)⁺.

D. 5-Bromo-1-ethyl-4-oxo-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid methyl ester

18 A solution of the ester (0.352 g, 1.0 mmol, prepared as described in Step C), in 10 ml of $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ (9:1, v/v) was added dropwise to a stirred solution of TEMPO- BF_4 in 10 mL of $\text{CH}_3\text{CN}-\text{H}_2\text{O}$ (9:1, v/v). Stirring was continued for 3 hours, and the reaction mixture was concentrated in vacuo. The residue was partitioned between Et_2O and H_2O . The organic phase was washed with brine and dried (Na_2SO_4). Removal of solvent afforded a yellow oil which was purified by flash chromatography (silica gel, hexane- EtOAc 2:1) to give 0.11 g of product as an off white solid.

1H NMR (DMSO- d_6 , 400 MHz): δ 0.817 (t, 3H, CCH_2CH_3), 1.98 (m, 1H, CCH_2CH_3), 2.16 (m, 1H, CCH_2CH_3), 2.93 (d, 1H, CCH_2CO), 3.19 (d, 2H,

- 21 -

CCH₂CO), 3.529 (s, 3H, OCH₃), 4.23 (q, 2H, CCH₂O), 7.15 (t, 1H, ArH), 7.41 (d, 1H, ArH), 7.49 (d, 1H, ArH), 12.36 (s, 1H, NH).

MS (m/z, EI): 365/367 (M)⁺, 336/338 (M-C₂H₅)⁺, 276/278 (b.p., M-CH₂COOCH₃)⁺.

5

E. (5-Bromo-1-ethyl-4-oxo-1,3,4,9-tetrahydro-pyrano[3,4-blindol-1-yl]-acetic acid 0.33 EtOAc + 0.16 Et₂O

A solution of the ester (0.10 g, 0.27 mmol, prepared as described in Step D) in 3 ml of ethanol and 1 ml of 1 N NaOH was stirred at ambient temperature overnight.

10 The solvent was evaporated and the residue partitioned between Et₂O and H₂O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted with Et₂O. The organic phase was dried with Na₂SO₄ and the solvent removed to provide crude product which was recrystallized from Et₂O to afford the title compound (0.04 g, 44%, white solid).

15 Analysis for: C₁₅H₁₄BrNO₄ + 0.33 EtOAc + 0.16 Et₂O

Calculated: C, 51.82; H, 4.68; N, 3.56.


Found: C, 51.88; H, 4.65; N, 3.47.

¹H NMR (DMSO-d₆, 400 MHz): δ 0.821 (t, 3H, CCH₂CH₃), 2.00 (m, 1H, CCH₂CH₃), 2.15 (m, 1H, CCH₂CH₃), 2.82 (d, 1H, CCH₂CO), 3.08 (d, 2H, CCH₂CO), 4.235 (q, 2H, CCH₂O), 7.14 (t, 1H, ArH), 7.40 (d, 1H, ArH), 7.48 (d, 1H, ArH), 12.25 (s, 1H, COOH), 12.357 (s, 1H, NH).

20 MS (m/z, EI): 351/353 (M⁺), 322/324, 306/308.

Example 7

25



5-Cyano-1-ethyl-4-oxo-1,3,4,9-tetrahydropyrano[3,4-blindole-1-acetic acid

30 A. 5-Cyano-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-blindole-1-acetic acid methyl ester

Under an atmosphere of nitrogen, a solution of the compound of Example 6 (0.409 g, 1.26mmol) and copper (I) cyanide (0.202 g, 2.27 mmol) in 10 ml of N-

- 22 -

methyl-2-pyrrolidinone was heated at 170 °C for 5 h. Upon cooling the reaction mixture was partitioned between EtOAc and H₂O. The mixture was vacuum filtered to remove dark solids. The layers were separated and the organic phase was washed 2 times with H₂O and brine. After drying (Na₂SO₄), the solvent was evaporated to 5 provide 0.50 g of crude solid which was purified by flash chromatography (silica gel, hexane-EtOAc 2:1) to give 0.145 g of the title compound.

10 ¹H NMR (DMSO-d₆, 400 MHz): δ 0.642 (t, 3H, CCH₃), 1.958 (q, 2H, CCH₂CH₃), 2.78 (d, 1H, CCH₂CO), 2.86 (m, 2H, CCH₂), 2.99 (d, 1H, CCH₂CO), 3.53 (s, 3H, OCH₃), 3.9 (m, 2H, CCH₂O), 7.18 (t, 1H, ArH), 7.44 (d, 1H, ArH), 7.66 (d, 1H, ArH), 11.482 (s, 1H, NH).

MS [EI, m/z]: 298 (M⁺), 269 (M-C₂H₅)⁺, 225 (M-CH₂CO₂Me)⁺, 195

B. 5-Cyano-1-ethyl-4-oxo-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid methyl ester

15 A solution of the ester (0.155 g, 0.52 mmol, prepared as described in Step A) in 5 ml of CH₃CN-H₂O (9:1, v/v) was added dropwise to a stirred solution of TEMPO-BF₄ in 5 ml of CH₃CN-H₂O (9:1, v/v). Stirring was continued for 48 h and the reaction mixture concentrated in vacuo. The residue was partitioned between Et₂O and H₂O. The organic phase was washed with brine and dried (Na₂SO₄). Removal of 20 solvent provided a yellow oil which was purified by flash chromatography (silica gel, hexane-EtOAc 2:1) to afford 0.110 g of product as an off white solid.

25 ¹H NMR (DMSO-d₆, 400 MHz): δ 0.837 (t, 3H, CCH₃), 1.97+2.17 (m, 2H, CCH₂CH₃), 2.97 (d, 1H, CCH₂CO), 3.21 (d, 1H, CCH₂CO), 3.52 (s, 3H, OCH₃), 4.29 (m, 2H, COCH₂O), 7.40 (t, 1H, ArH), 7.68 (d, 1H, ArH), 7.83 (d, 1H, ArH), 12.63 (s, 1H, NH).

MS (EI, m/z): 312 (M)⁺, 283 (M-C₂H₅)⁺, 239 (M-CH₂COOCH₃)⁺.

C. 5-Cyano-1-ethyl-4-oxo-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid


A solution of the ester (0.11 g, 0.35 mmol, prepared as described in Step B), in 30 3 ml of ethanol and 0.5 ml of 1 N NaOH was stirred at ambient temperature overnight. The solvent was evaporated and the residue partitioned between Et₂O and H₂O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted with Et₂O. The organic phase was dried with Na₂SO₄ and the solvent removed to provide the crude product as an oil. Trituration with Et₂O afforded the title compound 35 (0.061 g, 58%) as a white solid.

- 23 -

¹H NMR (DMSO-d₆, 400 MHz): δ 0.841 (t, 3H, CCH₃), 2.01 (m, 1H, CCH₂CH₃), 2.16 (m, 1H, CCH₂CH₃), 2.87 (d, 1H, CCH₂CO), 3.10 (d, 1H, CCH₂CO), 4.29 (m, 2H, COCH₂O), 7.39 (t, 1H, ArH), 7.67 (d, 1H, ArH), 7.83 (d, 1H, ArH), 12.29 (s, 1H, NH), 12.63 (s, 1H, COOH).

5 MS [EI, m/z]: 298 (M⁺), 269 (M-C₂H₅)⁺, 253 (b.p.).

Example 8



10

8-Allyl-1-ethyl-7-fluoro-4-oxo-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid

A. 8-Allyl-1-ethyl-7-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid methyl ester

15 A solution of 8-allyl-1-ethyl-7-fluoro-1,3,9-trihydropyran[3,4-b]indole-1-acetic acid (0.2 g, 0.63 mmol, Hughes et al *J. Heterocycl. Chem.* **27**, 2151-2163 (1990)) in 20 ml CH₃OH was treated portionwise with a 10% solution of trimethylsilyldiazomethane until a slight yellow color persisted. The solvent was removed to give 0.21 g of the product as a light yellow oil.

20 ¹H NMR (DMSO-d₆, 300 MHz): δ 0.6 (t, 3H, CCH₂CH₃), 1.95 (m, 2H, CCH₂CH₃), 2.6 (m, 2H, CCH₂), 2.78 (d, 1H, CCH₂CO), 2.95 (d, 2H, CCH₂CO), 3.5 (s, 3H, OCH₃), 3.6 (d, 2H, CH₂CH=CH₂), 3.9 (m, 2H, CCH₂O), 5.0 (m, 2H, CH₂CH=CH₂), 5.95 (m, 1H, CH₂CH=CH₂), 6.8 (m, 1H, ArH), 7.25 (m, 1H, ArH), 10.61 (s, 1H, NH).

25 B. 8-Allyl-1-ethyl-7-fluoro-4-oxo-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid methyl ester

A solution of the ester (0.21 g, 0.63 mmol, prepared as described in Step A), in 10 ml of CH₃CN-H₂O (9:1, v/v) was added dropwise to a stirred solution of TEMPO-30 BF₄ in 10 ml CH₃CN-H₂O (9:1, v/v). Stirring was continued for 2 h and the reaction

- 24 -

mixture was concentrated in vacuo. The residue was partitioned between Et₂O and H₂O. The organic phase was washed with brine and dried (Na₂SO₄). Removal of solvent provides a yellow oil which was purified by flash chromatography (silica gel, hexane- EtOAc 2:1) to give 0.18 g of product as an off white solid.

5 ¹H NMR (DMSO-d₆, 400 MHz): δ 0.808 (t, 3H, CCH₂CH₃), 1.96 (m, 1H, CCH₂CH₃), 2.23 (m, 1H, CCH₂CH₃), 2.91 (d, 1H, CCH₂CO), 3.266 (d, 2H, CCH₂CO), 3.51 (s, 3H, OCH₃), 3.66 (d, 2H, CH₂CH=CH₂), 4.25 (q, 2H, CCH₂O), 4.97 (m, 2H, CH₂CH=CH₂), 5.98 (m, 1H, CH₂CH=CH₂), 7.05 (m, 1H, ArH), 7.78 (m, 1H, ArH), 11.719 (s, 1H, NH).

10 ¹³C NMR (DMSO-d₆, 400 MHz): δ 188.959, 169.335, 158.6097, 156.25, 153.73, 135.64, 135.557, 135.132, 119.998, 119.2099, 119.1113, 115.46, 110.63...

MS (EI, m/z): 345 (M)⁺, 316 (M-C₂H₅)⁺, 272 (b.p., M-CH₂COOCH₃)⁺.

C. 8-Allyl-1-ethyl-7-fluoro-4-oxo-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid

15 A solution of the ester (0.19 g, 0.55 mmol, prepared as described in Step B), in 3 ml of ethanol and 1 ml of 1 N NaOH was stirred at ambient temperature overnight. The solvent was evaporated and the residue partitioned between Et₂O and H₂O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted 20 with Et₂O. The organic phase was dried with Na₂SO₄ and the solvent removed to provide 0.12 g of crude product which was recrystallized from Et₂O-hexane to afford the title compound (0.10 g, 55%, mp - 232-234 °C, off white solid).

Analysis for: C₁₈H₁₈FNO₄

Calculated: C, 65.25; H, 5.48; N, 4.23.


25 Found: C, 64.97; H, 5.45; N, 4.15.

¹H NMR (DMSO-d₆, 400 MHz): δ 0.809 (t, 3H, CCH₂CH₃), 1.99 (m, 1H, CCH₂CH₃), 2.21 (m, 1H, CCH₂CH₃), 2.79 (d, 1H, CCH₂CO), 3.17 (d, 2H, CCH₂CO), 3.66 (d, 2H, CH₂CH=CH₂), 4.255 (q, 2H, CCH₂O), 4.97 (m, 2H, CH₂CH=CH₂), 5.98 (m, 1H, CH₂CH=CH₂), 7.05 (m, 1H, ArH), 7.78 (m, 1H, ArH), 11.708 (s, 1H, NH), 12.208 (s, 1H, COOH).

MS (EI, m/z): 331 (M)⁺, 302 (M-C₂H₅)⁺, 272 (M-CH₂COOCH₃)⁺.

- 25 -

Example 9



5

[1-Ethyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)l-acetic acid]

To a solution of 1-ethyl-1,2,3,4-tetrahydro-carbazole-1-acetic acid (Asselin et al *J.Med. Chem.* **19**, 787-792 (1976), 0.289 g (1.12 mmole)) in methanol (10ml) was 10 added concentrated sulfuric acid (0.029 g) and the mixture was stirred at room temperature overnight. The methanol was removed and water added to the residue. 1N NaOH was added and the mixture extracted with ethyl acetate. The combined ethyl acetate extracts were dried (MgSO₄) and concentrated to the oily ester was dissolved in 9:1 tetrahydrofuran-water (3 ml) and chilled to 0 °C. 2,3 -Dichloro-5,6-dicyano-1,4- 15 benzoquinone (0.130 g, 0.574 mmole) was dissolved in tetrahydrofuran (1.1 ml) and added dropwise to the chilled solution. After 2 h the solvent was removed and the residue taken into ethyl acetate, washed several times with 1N NaOH, dried (MgSO₄) and concentrated to an oil. Flash chromatography (eluting with 2% ethyl acetate-methylene chloride) affords the ester which was hydrolyzed to the title compound 20 utilizing the method of Example 5 (LiOH, H₂O/THF). The title compound was obtained as a white solid (0.077 g), m.p. 214-216°C.

Analysis for: C₁₆ H₁₇ N O₃.


Calculated: C, 70.83; H, 6.32; N, 5.16.

Found: C, 70.54; H, 6.41; N, 5.10.

25

- 26 -

Example 10



5

[1,8-Diethyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)-acetic acid]

The title compound was prepared according to the method of Example 9 using 0.490 g (1.71mmole) of 1,8-diethyl-1,2,3,4-tetrahydrocarbazole-1-acetic acid (Asselin et al., *J.Med. Chem* 19, 787-792 (1976)). The title compound was obtained as a white powder (0.197 g), m.p. 212-214°C.


Analysis for: C₁₈ H₂₁ N O₃

Calculated: C, 72.22; H, 7.07; N, 4.68.

Found: C, 72.29; H, 7.03; N, 4.61

15

Example 11




20 **[1-Ethyl-8-isopropyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)-acetic acid]**

The title compound was prepared according to the method of Example 9 using 0.490 (1.71 mmole) of 1,8-diethyl-1,2,3,4-tetrahydrocarbazole-1-acetic acid (Asselin et al., *J.Med. Chem* 19, 787-792 (1976)). The title compound was obtained as a light yellow solid (0.027 g, 55%), having a melting point of 240-242°C.

25 Analysis for: C₁₉ H₂₃ N O₃

Calculated: C, 72.82; H, 7.40; N, 4.47.

Found: C, 72.24; H, 7.51; N, 4.26.

Example 12

5

[1-Ethyl-5-chloro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)-acetic acid]A. [1-Ethyl-5-chloro-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)lacetic acid methyl ester]

10 A solution of 3-chlorophenylhydrazine (154 mmol) and 27.9 g of methyl 1-ethyl-2-oxocyclohexaneacetate (Asselin et al., *J.Med. Chem.* **19**, 787-792 (1976), 140.6 mmol) in toluene (Dean-Stark trap) was refluxed for 43 hr. Removal of the solvent afforded 56.5 g of the crude hydrazone which was cyclized by refluxing for 1.5 h in 300 ml acetic acid containing 17 ml of BF_3 etherate. The reaction mixture was then cooled and poured into 750 ml of ice/water and extracted with 3x200 ml Et_2O . The combined ether extract was washed subsequently with 100 ml H_2O , 2x115 ml 0.5 N HCl, 2x 100 ml 2.5 N NaOH (100 ml H_2O was added to separate layers) and 115 ml H_2O , dried over MgSO_4 and evaporated to provide 39.5 g of a red liquid. Column chromatography (silica gel, eluting with CH_2Cl_2) gave a 1:1 mixture of the 5 and 7 chloro isomeric esters which were separated by HPLC (hexane/ethyl acetate gradient) to afford the pure 5-chloro ester, m.p. 101-104°C (note the 7-chloro ester was a liquid).

B. [1-Ethyl-5-chloro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)-acetic acid 0.4 $\text{C}_4\text{H}_8\text{O}_2$


25 The title compound was prepared according to the method of Example 5 using 0.76 g (2.49 mmole) of 1-[ethyl-5-chloro-2,3,4,9-tetrahydro-1H-(carbazol-1-yl)-acetic acid methyl ester, and was obtained as a white solid, 202-205°C.

Analysis for: $\text{C}_{16}\text{H}_{10}\text{ClN O}_3 \cdot 0.4 \text{C}_4\text{H}_8\text{O}_2$

Calculated: C, 61.99; H, 5.68; N, 4.11.

30 Found: C, 62.19; H, 5.76; N, 3.90.

MS: (EI m/z) $[\text{M}^+]$ 305/307

Example 13

5

(1-Ethyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid

A. **(1-Ethyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester**

10 The title compound was prepared according to the method of Example 12, Step A using 20.6 g (0.104 mole) of methyl-1-ethyl-2-oxo-cyclohexane acetate [(Asselin et al *J.Med. Chem.* **19**, 787-792 (1976)] and 2,5 difluorophenylhydrazine. A crystalline solid (7.35 g, 23%) was obtained having a melting point of 97-99°C.

15 **Analysis for:** C₁₇H₁₉F₂N O₂

Calculated: C, 66.44; H, 6.23; N, 4.56

Found: C, 66.15; H, 6.13; N, 4.42


B. **(1-Ethyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid**

20 The title compound was prepared according to the method of Example 5 using 0.200 g (0.622 mmole) of the ester prepared in Step A. The title compound was obtained as a white powder (0.095 g, 50%) having a melting point of 226-229°C.

Analysis for: C₁₆H₁₅F₂N O₃

Calculated: C, 62.54; H, 4.92; N, 4.56

25 **Found:** C, 62.78; H, 5.07; N, 4.23

Example 14

5

(7,8-Difluoro-1-ethyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid.

To a stirred solution at room temperature under nitrogen of (7,8-difluoro-1-ethyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))acetic acid methyl ester (prepared from 2,3 difluorophenyl hydrazine according to the method of Example 12, Step A, 0.31 g, 1 mmol) in 5 ml of benzene and 5 ml of pH 4 buffer was added dropwise over 1.5 h, a solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.522 g, 2.3 mmol) in benzene (30 ml). After 4 h of stirring when the TLC showed ~90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml), and sodium sulfite (10 ml of a 10% solution). The resulting mixture was stirred for ~10 min (until substantial discoloration occurred), and diluted with 1 N NaOH (20 ml). The reaction mixture was extracted with ethyl acetate (50 ml x 3). Evaporation of the solvent gave a light brown powder. Purification by flash chromatography (1:1 ethyl acetate:hexane) afforded 0.240 g (72%) of methyl ester which gave after hydrolysis (24 h, MeOH- 1 N NaOH), 0.200 g (90%) of the desired product as a white solid, m.p. 259-261°C.

20 **Analysis for:** C₁₆H₁₅NO₃F₂


Calculated: C, 62.54; H, 4.92; N, 4.56.

Found: C, 62.60; H, 5.16 ; N, 3.90.

1H NMR (400 MHz, DMSO) δ 12.30 (s, 1 H), 12.20 (s, 1 H), 7.18 - 7.72 (m, 2 H), 2.75 - 3.05 (dd, 2 H), 2.2 - 2.6 (m, 4 H), 1.88 (m, 2 H).

25 **IR** (KBr, cm⁻¹): 3240, 2950, 1700, 1660, 1530, 1465

MS (EI m/z): 307, 278, 248.

Example 15

5

(1-Allyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acidA. (1-Allyl-5,8-difluoro-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester

10 To a solution of methyl-1-allyl-2-oxo-cyclohexane acetate [prepared analogous to *J. Med. Chem.* 19, 787 (1976): 19.68 g, 0.094 mole] in toluene (200 ml) was added 2,5-difluorophenylhydrazine (15g, 0.104 mole). The mixture was refluxed for 24 hours as water was collected in a Dean-Stark trap. The toluene was removed and to the residue was added glacial acetic acid (200 ml) and boron trifluoride diethyl etherate (17.34g, 0.122 mole). After refluxing for one hour, the mixture was poured into ice (500 ml) and extracted with ether. The combined extracts were washed sequentially with water, 0.5N HCl, 0.5N NaOH and water, dried ($MgSO_4$) and concentrated to a dark oil. The oil was purified by passing through a thick pad of silica gel (eluted with 5-15% ether-hexane) to give 8.58 (28%) orange oil which crystallized upon sitting, m.

15 20 p. 78-80°C.

B. (1-Allyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester

25 A solution of $TEMPO^+BF_4^-$ [Bobbitt, J. M., et. al., *Heterocycles* 30: 1131 (1990); 0.760 g, 3.13 mmole] in 9:1 acetonitrile-water (20 ml) was added dropwise to a solution of the ester prepared according to Step A (0.5g, 1.56 mmole) in 9:1 acetonitrile-water (20 ml). The reaction was stirred at room temperature for 2.5 hours then the solvent was removed. Water was added to the residue and this extracted with ethyl acetate, dried ($MgSO_4$) and concentrated to a solid. Purification of the solid by 30 flash chromatography (eluted with 95:5 methylene chloride-ethyl acetate) afforded a white solid (0.450 g, 86%), m. p. 179-181°C.

- 31 -

Analysis for: C₁₈ H₁₇ F₂ N O₃

Calculated: C, 64.86; H, 5.14; N, 4.20.

Found: C, 64.55; H, 4.98; N, 4.08.

5 C. (1-Allyl-5,8-difluoro-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid


To a solution of the ester prepared in Step B (0.250 g, 0.075 mmole) in tetrahydrofuran (6 ml) was added 1N lithium hydroxide (3 ml) and the mixture was stirred overnight. After removing the solvent, water was added to the residue and this was extracted with methylene chloride. The aqueous layer was acidified (pH 2) and the 10 resulting solid collected, taken into ethyl acetate, dried (MgSO₄) and concentrated. The residue was recrystallized (ethyl acetate-hexane) to afford 0.120 g (50%) of white solid, m. p. 205-206°C.

Analysis for: C₁₇ H₁₅ F₂ N O₃

Calculated: C, 63.95; H, 4.74; N, 4.39

15 Found: C, 63.84; H, 4.57; N, 4.32

Example 16



20

(5,8-Difluoro-4-oxo-1-propyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid

25 A. (5,8-Difluoro-1-propyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester

A mixture of the ester prepared according to Step A of Example 15 (1.0 g, 3.13 mmole) and 10% palladium on carbon (0.050 g) in methanol (30 ml) was shaken on a Parr hydrogenation apparatus starting at 50 psi for 2 h. The catalyst was removed and the filtrate concentrated to yield 0.940 g (94%) of a white solid, m. p. 104-106°C.

30

- 32 -

5 B. (5,8-Difluoro-4-oxo-1-propyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester

The title compound was prepared according to the method of Example 15, Step B using 0.855 g (2.66 mmole) of the ester of Step A, as a white solid (0.690 g, 77%) having a melting point of 205-207°C.

10 Analysis for: C₁₈ H₁₉ F₂ N O₃

Calculated: C, 64.47; H, 5.71; N, 4.18.

Found: C, 64.38; H, 5.68; N, 4.10.

15 C. (5,8-Difluoro-4-oxo-1-propyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid

The title compound was prepared according to the method of Example 15, Step C using 0.550 g (1.64 mmole) of the ester produced in Step B. A white solid (0.271 g, 51%) was obtained having a melting point of 236-238°C.


15 Analysis for: C₁₇ H₁₇ F₂ N O₃

Calculated: C, 63.55; H, 5.33; N, 4.36.

Found: C, 63.34; H, 5.25; N, 4.28.

20

Example 17



25 (5,7-Difluoro-1-propyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid.

A. (5,7-Difluoro-1-propyl-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid methyl ester.

20 A mixture of 2,5-difluorophenylhydrazine hydrochloride (10 mmol), 2-propyl-2-(methoxycarbonyl)methylcyclohexanone (Asselin et al *J.Med. Chem.* **19**, 787-792 (1976), 11 mmol), and sodium acetate (12 mmol) was stirred in methanol (50 ml) for 0.5 - 4 h at room temperature until reaction was complete (monitored by TLC). The

- 33 -

residue after evaporation of the methanol was redissolved in ethyl acetate (100 ml), washed with 1 N HCl (50 ml), pH 7 buffer (50 ml), brine, and dried over sodium sulfate. Evaporation of the solvent afforded essentially pure hydrazone. The latter was dissolved in glacial acetic acid (20 ml) and after addition of boron trifluoride etherate (10-12 mmol), quickly heated to reflux. Stirring at reflux was continued until there was complete consumption of hydrazone (usually 20-45 min). After cooling, the mixture was quenched with saturated sodium bicarbonate solution (100 ml) and extracted with ethyl acetate (2 x 100 ml). The combined organics were washed with brine and dried over sodium sulfate. The crude material that was obtained after evaporation of ethyl acetate was purified by flash chromatography (2-10 % EtOAc/hexane) and used as such in the next step.

B. (5,7-Difluoro-1-propyl-4-oxo-2,3,4,9-tetrahydro-1H-(carbazol-1-yl))-acetic acid.

15 To a stirred solution at room temperature under nitrogen of (5,7-difluoro-1-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)acetic acid methyl ester (0.32 g, 1 mmol) in 5 ml of benzene and 5 ml of pH 4 buffer was added dropwise over 1.5 h, a solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.522 g, 2.3 mmol) in benzene (30 ml). After 4 h of stirring when the TLC shows ~90% conversion, the mixture was 20 diluted with water (25 ml), ethyl acetate (50 ml) and 10% sodium sulfite (10 ml). The resulting mixture was stirred for ~10 min (until substantial discoloration occurred) and diluted with 1 N NaOH (20 ml). Extraction of the reaction mixture with ethyl acetate (50 ml x 3) followed by evaporation of the solvent gave a light brown powder which was purified by flash chromatography (1:1 ethyl acetate:hexane) to afford 0.210 g 25 (63%) of the methyl ester. Hydrolysis (24 h, MeOH - 1 N NaOH) gave 0.182 g (90%) of the desired product as a white solid, m.p. 250-252°C.

Analysis for: C₁₇H₁₇NO₃F₂


Calculated: C, 62.54; H, 4.92; N, 4.56 .

Found: C, 62.15; H, 5.10 ; N, 4.24.

30 ¹H NMR (400 MHz, DMSO) δ 12.2 (s, 1 H), 12.1 (s, 1 H), 6.8 - 7.1 (m, 2 H), 2.6 - 2.9 (dd, 2 H), 2.0 - 2.3 (m, 2 H), 0.84 (t, 3 H).

IR (KBr, cm⁻¹): 3250, 2950, 1700, 1630, 1450

MS [(-)FAB m/z]: 320

Example 18

5

[1,8-Diethyl-4-hydroxyimino-1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]- acetic acidA. [1,8-Diethyl-4-hydroxyimino-1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]- acetic acid methyl ester

10 The ester of Example 4, Step B (0.5 g, 1.6mmol), hydroxylamine hydrochloride (0.17 g, 2.4mmol), and 25 ml pyridine were refluxed for 3.5 h. The reaction mixture was poured into water, extracted with CHCl₃. The organic phase was then washed with 1.0N HCl, water, dilute NaHCO₃, water, and brine, dried (MgSO₄) and evaporated to yield a crude solid which was purified by filtration through a pad of 15 silica gel and celite. The product , 0.33 g was isolated as a solid, m. p. 188-190°C

Analysis for: C₁₈ H₂₂ N₂ O₄

Calculated: C, 65.44; H, 6.71; N, 8.48.

Found: C, 65.59; H, 6.80; N, 8.27

20 B. [1,8-Diethyl-4-hydroxyimino-1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]- acetic acid 0.06 ethyl acetate.


The product of Step A (0.182 g, 0.55 mmol), K₂CO₃ (0.1 g, 0.71 mmol) and a MeOH-H₂O mixture (10 ml-1 ml) were refluxed for 3 h. The reaction mixture was cooled to room temperature and the methanol was removed. To the reaction mixture 25 was added 10 ml H₂O, which was then acidified using 1 N HCl. The aqueous phase was extracted with EtOAc, which was dried (MgSO₄), evaporated and triturated using hexane to yield a solid, m.p. 165-168°C (dec.).

Analysis for: C₁₇ H₂₀ N₂ O₄ .0.06 EtOAc

Calculated: C, 64.38; H, 6.41; N, 8.71.

30 Found: C, 64.08; H 6.48; N, 8.21.

- 35 -

Example 19

[1,8-Diethyl-4-(methanesulfonyl-hydrazone)-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl]-acetic acid sodium salt.

10 A. [1,8-Diethyl-4-(methanesulfonyl-hydrazone)-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl]-acetic acid methyl ester.

To the ester of Example 4, Step B (0.5 g, 1.6 mmol) was added 10 ml MeOH, 0.4 ml 1N HCl and 0.37 ml H₂O. The mixture was stirred one minute followed by addition of CH₃SO₂NHNH₂ all at once. After overnight stirring, the MeOH was 15 evaporated and additional water was added. This aqueous phase was twice extracted with CH₂Cl₂. The organic phase was concentrated to a crude solid and purified by flash chromatography using CH₂Cl₂-EtOAc 95-5 as eluent. The product 0.33 g, was obtained as a solid m.p. 80-82°C.

20 MS (EI, m/z): 407 (M)⁺.

B.


[1,8-Diethyl-4-(methanesulfonyl-hydrazone)-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl]-acetic acid sodium salt.

The title compound was prepared according to the method of Example 18, Step B using 0.2 g (0.49 mmol) of the ester from Step A. Trituration in ethyl ether gave the 25 product 0.12 g, as a solid, m.p. 187-190°C.

MS [(-)FAB m/z]: 392 (M)⁺.

- 36 -

Example 20



5

(1,8-Diethyl-4-hydroxyimino-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-acetic acid

The title compound was prepared according to the method of Example 18, using of the ester from Example 10. The title compound was obtained as a white solid, m.p. 203-206°C.


10 **Analysis for:** C₁₈H₂₂N₂O₃

Calculated: C, 68.77; H, 7.05; N, 8.91.

Found: C, 68.40; H 7.11; N, 8.82.

WHAT IS CLAIMED IS:

1. A compound of formula I having the structure



5

wherein

R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

R₅ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

R₆ is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

X is oxygen or methylene;

A is NZ;

Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R₆ is hydrogen or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2, wherein R₅ is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or a pharmaceutically acceptable salt thereof.


4. The compound according to claim 1, which is [1,8-diethyl-4-hydroxyimino-1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]- acetic acid or a pharmaceutically acceptable salt thereof.

5

5. The compound according to claim 1, which is [1,8-diethyl-4-(methanesulfonylhydrazone)-1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]-acetic acid sodium salt.

6. The compound according to claim 1, which is (1,8-diethyl-4-hydroxyimino-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-acetic acid or a pharmaceutically acceptable salt thereof.

7. A method of treating arthritic disorders in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula 15 I having the structure



wherein

20 R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

25 R₅ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

30 R₆ is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

X is oxygen or methylene;

- 39 -


A is NZ;

Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

5

8. A method of treating colorectal cancer in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula I having the structure



10

wherein

R1, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, 15 alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

20 R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

25 X is oxygen or methylene;

A is oxygen or NZ;


Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, 30 arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

30

- 40 -

9. A method of treating Alzheimer's disease in a mammal which comprises administering to said person an effective amount of a compound of formula I having the structure



5

wherein

R1, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

X is oxygen or methylene;


A is oxygen or NZ;

Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

25 or a pharmaceutically acceptable salt thereof.

- 41 -

10. A pharmaceutical composition which comprises a compound of formula I having the structure



5

wherein

R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

10 R₅ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

15 R₆ is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

X is oxygen or methylene;


20 A is NZ;

Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.

- 42 -

11. A process for the preparation of a compound of formula I having the structure



wherein

5 R₁, R₂, R₃ and R₄ are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;

10 R₅ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms;

15 R₆ is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

16 X is oxygen or methylene;

17 A is NZ;

18 Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms;

20 or a pharmaceutically acceptable salt thereof, which comprises

21 (a) reaction of a compound having the formula I where A is oxygen and R₁, R₂, R₃, R₄, R₅ and X are as defined above or a salt thereof with a compound having the formula H₂NZ where Z is as defined above to prepare a compound having formula I as illustrated above where A is NZ and R₁, R₂, R₃, R₄, R₅, R₆, and X are as defined above or a salt thereof; or

22 (b) hydrolysis of a compound having formula I as illustrated above where A, R₁, R₂, R₃, R₄, R₅ and X are as defined above and R₆ is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms so as to form a compound having formula I as illustrated above where A, R₁, R₂, R₃, R₄, R₅, R₆ and X are as defined above and R₆ is hydrogen or a salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/12782

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D209/88 C07D491/052 A61K31/40 // (C07D491/052, 311:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 686 213 A (FERDINANDI ECKHARDT S ET AL) 11 August 1987 cited in the application see the whole document ---	1-11
A	US 4 927 842 A (MOBILIO DOMINICK) 22 May 1990 see the whole document ---	1-11
A	LESLIE G. HUMBER ET AL: "Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites" JOURNAL OF MEDICINAL CHEMISTRY., vol. 31, no. 9, 1987, WASHINGTON US, pages 1712-1719, XP002046067 cited in the application see the whole document -----	1-11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
7 November 1997	18.11.97
Name and mailing address of the ISA European Patent Office, P.O. Box 5818 Patentsteen 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Henry, J

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 97/12782

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos... because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 7-9 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos... because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos... because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment or any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 97/12782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4686213 A	11-08-87	US 4748252 A	31-05-88
US 4927842 A	22-05-90	US 5055590 A	08-10-91